Confirmed Vaping Deaths and EVALI Case Counts in 2024
Public health agencies reported a continued decline in confirmed vaping-related deaths in 2024 compared with the 2019 EVALI outbreak peak, with the CDC tracking a small number of severe lung injury cases tied to illicit THC cartridges and vitamin E acetate contamination. The latest surveillance data show that most fatalities involved hospitalized patients with a history of using unregulated products purchased on informal markets, and the CDC updates its EVALI case definitions and reporting guidance on its official site cdc.gov.
Hospitalization rates for acute vaping-related lung injury fell sharply in 2024 as state health departments adopted standardized case reporting and toxicology screening protocols, while the FDA and CDC emphasized that no deaths have been conclusively linked to regulated nicotine vaping products sold through licensed retailers fda.gov.
Regulatory Actions, Company Responses, and Market Impact
The FDA maintained its enforcement posture against unauthorized e-cigarette products in 2024, issuing warning letters and import alerts for disposable vapes that failed premarket tobacco application requirements, while Juul Labs faced ongoing scrutiny over marketing practices and product design choices that regulators say appeal to youth sec.gov.
Major tobacco and vaping companies adjusted their 2024 capital expenditure plans and litigation reserves in response to state-level flavor bans, FDA marketing denial orders, and rising insurance costs tied to product liability claims, with financial analysts noting that the legal and regulatory environment continues to shape valuation multiples and merger-and-acquisition activity in the sector.
Key Risk Factors, Demographic Patterns, and Public Health Guidance
Epidemiological reviews published in 2024 reaffirm that the strongest risk factor for severe vaping-related lung injury is the use of THC-containing products obtained from informal sources, with vitamin E acetate and other cutting agents identified as primary chemical culprits in lung biopsy and bronchoalveolar lavage analyses.
Public health agencies recommend that consumers avoid all vaping products purchased outside licensed retail channels, seek immediate medical care for respiratory symptoms such as shortness of breath, chest pain, or gastrointestinal distress, and report adverse events through the FDA Safety Reporting Portal to support ongoing surveillance efforts fda.gov.